Hypercoagulability and nephrotic syndrome

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 512-517

  Gigante, Antonietta ^a   Barbano, Biagio ^a   Sardo, Liborio ^a   Martina, Paola ^a   Gasperini, Maria L ^a   Labbadia, Raffaella ^a   Liberatori, Marta ^a   Amoroso, Antonio ^a   Cianci, Rosario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Arterial thrombosis; Deep venous thrombosis; Nephrotic syndrome; Proteinuria; Renal venous thrombosis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; DABIGATRAN; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; ROSUVASTATIN; TICLOPIDINE; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD VISCOSITY; DEEP VEIN THROMBOSIS; GLOMERULONEPHRITIS; HEMOSTASIS; HYPERCOAGULABILITY; HYPOALBUMINEMIA; KIDNEY VEIN THROMBOSIS; LUNG EMBOLISM; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PLATELET REACTIVITY; PROPHYLAXIS; PROTEINURIA; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 84922393388     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111203140518172048     Document Type: Article

References (72)

1. [1] Nachman PH, Jennette JC, Falk RJ. Primary Glomerular Disease in: Brenner and Rector's The Kidney, 8th ed., Saunders 2007: pp. 987-1042.
2. [2] Jennette JC, Olson JL, Schwartz MM, et al. Heptinstall's Pathology of the Kidney, 6th ed. Lippincott Williams & Wilkins 2007; pp 126-49.
3. [3] Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysi- ology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7: 513-20.
4. [4] Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18: 2221-5.
5. [5] Singhal R, Brimble KS. Thrombo-embolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res 2006; 118: 397-407.
6. [6] Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis. Am J Med 1980; 69: 819-27.
7. [7] Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosis in idiopathic membranous nephropathy and nephritic syndrome: Incidence and significance. Kidney Int 1983; 23: 368-74.
8. [8] Velasquez FF, Garcia PN, Ruiz MN. Idiopathic nephrotic syn- drome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 1988; 8: 457-62.
9. [9] Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospec- tive cohort study. Circulation 2008; 15; 117: 224-30.
10. [10] Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syn- drome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155: 105-10.
11. [11] Ulinski T, Guigonis V, Baudet-Bonneville V, et al. Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome. Pediatr Nephrol 2003; 18: 1295-7.
12. [12] Ponticelli C, Glassock Richard J. Treatment of primary glomerulonephritis. Oxford, 2nd edition 2009; 21-26.
13. [13] Anderson S, Komers R, Brenner BM. Renal and systemic manifes- tations of glomerular disease in Brenner and Rector's The Kidney, 8th ed., Saunders 2007: pp. 821-3.
14. [14] Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet func- tion: relevance to atherogenesis and thrombosis. Platelets 1996; 7: 125-37.
15. [15] Remuzzi G, Mecca G, Marchesi D, et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979; 16: 345-54.
16. [16] Shaper AG, Wannamethee SG and Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004; 57: 195-202.
17. [17] Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362: 629-39.
18. [18] Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton) 2008; 13: 45-50.
19. [19] Radhakrishnan J. Venous thromboembolism and membranous nephropathy: so what’s new? Clin J Am Soc Nephrol 2012; 7: 3-4.
20. [20] Citak A, Emre S, Sâirin A, Bilge I, et al. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol 2000; 14: 138-42.
21. [21] Chemg SC, Huang WS, Wang YF, et al. The role of lung scintigra- phy in the diagnosis of nephrotic syndrome with pulmonary embo- lism. Clin Nucl Med 2000; 25: 167-72.
22. [22] Ozkayin N, Mir S, Kavakli K. Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity. Int Urol Nephrol 2004; 36: 599-603.
23. [23] Vigano-D’Angelo S, D’Angelo A, Kaufman Jr CE, et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987; 107: 42-7.
24. [24] Al-Mugeiren MM, Abdel Gader AG, Al-Rasheed SA, et al. Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol 2006; 21: 771-7.
25. [25] Castellino P, Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clinl Nutr Metab Care 2002; 5: 51-4.
26. [26] Bellomo R, Atkins RC. Membranous nephropathy and throm- boembolism: is prophylactic anticoagulation warranted? Nephron 1993; 63: 249-54.
27. [27] Jensen H, Rossing N, Andersen SB, Jarnum S. Albumin metabo- lism in the nephrotic syndrome in adults. Clin Sci 1967; 33: 445-57.
28. [28] Yssing M, Jensen H, Jarnum S. Albumin metabolism and gastroin- testinal protein loss in children with nephrotic syndrome. Acta Pae- diatr Scand 1969; 58: 109-15.
29. [29] De Sain-van der Velden MG, Kaysen GA, de Meer K, et al. Pro- portionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes. Kidney Int 1998; 53: 181-8.
30. [30] Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-59.
31. [31] Milionis HJ, Liberopoulos E, Goudevenos J, et al. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99: 269-75.
32. [32] Levenson J, Giral P, Megnien JL, et al. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hyper- cholesterolemic men. Arterioscler Thromb Vasc Biol 1997; 17: 45-50.
33. [33] Fowkes FG, Lowe GD, Housley E, et al. Cross-linked fibrin degra- dation products, progression of peripheral arterial disease and risk of coronary heart disease. Lancet 1993; 342: 84-86.
34. [34] Kanfer A, Kleinknecht D, Broyer M, et al. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 1970; 24: 562-71.
35. [35] Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-39.
36. [36] Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23: 271-80.
37. [37] Kuipers S, Cannegieter SC, Doggen CJ, et al. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood 2009; 113: 2064-9.
38. [38] Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: The longitu- dinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-42.
39. [39] Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338: 1202-11.
40. [40] Remuzzi G, Marchesi D, Mecca G, et al. Platelet hypersensitivity in the nephrotic syndrome. Proc Eur Dial Transplant Assoc 1979; 16: 487-94.
41. [41] Walter E, Deppermann D, Andrassy K, et al. Platelet hyperaggre- gability as a consequence of the nephrotic syndrome. Thromb Res 1981; 23: 473-9.
42. [42] Sirolli V, Ballone E, Garofalo D, et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of dif- ferent platelet function tests. Nephron 2002; 91: 424-30.
43. [43] Zwaginga JJ, Koomans HA, Sixma JJ, et al. Thrombus formation and platelet—vessel wall interaction in the nephrotic syndrome un- der flow conditions. J Clin Invest 1994; 93: 204-11.
44. [44] Soulat T, Loyau S, Baudouin V, et al. Effect of individual plasma lipoprotein (a) variations in vivo on its competition with plasmino- gen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol 2000; 20: 575-84.
45. [45] Svenningsen P, Bistrup C, Friis UG, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20: 299-310.
46. [46] Thomson C, Forbes CD, Prentice CR, et al. Changes in blood co- agulation and fibrinolysis in the nephrotic syndrome. Q J Med 1974; 43: 399-407.
47. [47] Rabelink TJ, Zwaginga JJ, Koomans HA, et al. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-96.
48. [48] Yoshida Y, Shiiki H, Iwano M, et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syn- drome. Nephron 2001; 88: 24-9.
49. [49] Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflam- mation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-42.
50. [50] Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007; 38: 1959-66.
51. [51] Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart dis- ease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-7.
52. [52] Kanfer A. Coagulation factors in nephrotic syndrome. Am J Neph- rol 1990; 10 (Suppl 1): 63-8.
53. [53] Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp 1984; 13: 75.
54. [54] Egli F, Elmiger P, Stalder G. Thrombosis as a complication of nephrotic syndrome. Helv Paediatr Acta 1973; 30: 20-1.
55. [55] Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg 2005; 107: 371-8.
56. [56] Lionaki S, Derebail V, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7: 43-51.
57. [57] Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76: 1011-6.
58. [58] Igarashi M, Roy S 3rd, Stapleton FB. Cerebrovascular complica- tions in children with nephrotic syndrome. Pediatr Neurol 1988; 4: 362-5.
59. [59] Brahmbhatt BK, Mathew A, Rajesh R, et al. Brachiocephalic artery thrombosis in adult nephrotic syndrome. Indian J Nephrol 2011; 21: 204-7.
60. [60] Ueda N, Kawaguchi S, Niinomi Y, et al. Effect of corticosteroids on coagulation factors in children with nephrotic syndrome. Pediatr Nephrol 1987; 1: 286-9.
61. [61] Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128: 2203-10.
62. [62] Lai S, Barbano B, Cianci R, et al. The risk of bleeding associated with low molecular weight heparin in patients with renal failure. G Ital Nefrol 2010; 27: 649-54.
63. [63] Radhakrishnan J. Renal vein thrombosis and hypercoagulable state in nephrotic syndrome. [Online] 2012 Up To Date, avalaible at http://www.uptodate.com/contents/renal-vein-thrombosis-and-hypercoagulable-state-in-nephrotic-syndrome
64. [64] Markowitz GS, Brignol F, Burns ER, et al. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis 1995; 25: 801-6.
65. [65] Resh M, Mahmoodi BK, Navis GJ, et al. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res 2011; 127: 395-9.
66. [66] Paraskevas KI, Bessias N, Perdikides TP, Mikhailidis DP. Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin 2009; 25: 1807-9.
67. [67] Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-13.
68. [68] Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a random- ized trial. Ann Intern Med 2007; 147: 525-33.
69. [69] Akoglu H, Agbaht K, Piskinpasa S, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1460-6.
70. [70] Tholl U, Anlauf M, Helmchen U. Clopidogrel and membranous nephropathy. Lancet 1999; 354: 1443-4.
71. [71] Alberts MJ, Bernstein RA, Naccarelli GV, et al. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43: 271-9.
72. [72] Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term An- ticoagulation Therapy) trial. Circulation 2012; 125: 669-76.